365 related articles for article (PubMed ID: 29695053)
1. VEGF (Vascular Endothelial Growth Factor) and Fibrotic Lung Disease.
Barratt SL; Flower VA; Pauling JD; Millar AB
Int J Mol Sci; 2018 Apr; 19(5):. PubMed ID: 29695053
[TBL] [Abstract][Full Text] [Related]
2. Endotype-phenotyping may predict a treatment response in progressive fibrosing interstitial lung disease.
Hoffmann-Vold AM; Weigt SS; Saggar R; Palchevskiy V; Volkmann ER; Liang LL; Ross D; Ardehali A; Lynch JP; Belperio JA
EBioMedicine; 2019 Dec; 50():379-386. PubMed ID: 31732480
[TBL] [Abstract][Full Text] [Related]
3. The Bleomycin Model of Pulmonary Fibrosis.
Liu T; De Los Santos FG; Phan SH
Methods Mol Biol; 2017; 1627():27-42. PubMed ID: 28836192
[TBL] [Abstract][Full Text] [Related]
4. Effects of hypoxia and hyperoxia on the differential expression of VEGF-A isoforms and receptors in Idiopathic Pulmonary Fibrosis (IPF).
Barratt SL; Blythe T; Ourradi K; Jarrett C; Welsh GI; Bates DO; Millar AB
Respir Res; 2018 Jan; 19(1):9. PubMed ID: 29334947
[TBL] [Abstract][Full Text] [Related]
5. Pathological Insight into 5-HT
Löfdahl A; Tornling G; Wigén J; Larsson-Callerfelt AK; Wenglén C; Westergren-Thorsson G
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33379351
[TBL] [Abstract][Full Text] [Related]
6. Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis.
Hostettler KE; Zhong J; Papakonstantinou E; Karakiulakis G; Tamm M; Seidel P; Sun Q; Mandal J; Lardinois D; Lambers C; Roth M
Respir Res; 2014 Dec; 15(1):157. PubMed ID: 25496490
[TBL] [Abstract][Full Text] [Related]
7. A cohort study of Danish patients with interstitial lung diseases: burden, severity, treatment and survival.
Hyldgaard C
Dan Med J; 2015 Apr; 62(4):B5069. PubMed ID: 25872544
[TBL] [Abstract][Full Text] [Related]
8. Pulmonary 5-HT
Löfdahl A; Nybom A; Wigén J; Dellgren G; Brunnström H; Wenglén C; Westergren-Thorsson G
Acta Histochem; 2023 Apr; 125(3):152024. PubMed ID: 36958084
[TBL] [Abstract][Full Text] [Related]
9. Review series: Aspects of interstitial lung disease: connective tissue disease-associated interstitial lung disease: how does it differ from IPF? How should the clinical approach differ?
de Lauretis A; Veeraraghavan S; Renzoni E
Chron Respir Dis; 2011; 8(1):53-82. PubMed ID: 21339375
[TBL] [Abstract][Full Text] [Related]
10. Extracellular Heat Shock Proteins as Therapeutic Targets and Biomarkers in Fibrosing Interstitial Lung Diseases.
Tanguy J; Pommerolle L; Garrido C; Kolb M; Bonniaud P; Goirand F; Bellaye PS
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502225
[TBL] [Abstract][Full Text] [Related]
11. The role of tyrosine kinases in the pathogenesis of idiopathic pulmonary fibrosis.
Grimminger F; Günther A; Vancheri C
Eur Respir J; 2015 May; 45(5):1426-33. PubMed ID: 25745048
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic targets in idiopathic pulmonary fibrosis.
Kolb M; Bonella F; Wollin L
Respir Med; 2017 Oct; 131():49-57. PubMed ID: 28947042
[TBL] [Abstract][Full Text] [Related]
13. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis.
Wollin L; Wex E; Pautsch A; Schnapp G; Hostettler KE; Stowasser S; Kolb M
Eur Respir J; 2015 May; 45(5):1434-45. PubMed ID: 25745043
[TBL] [Abstract][Full Text] [Related]
14. Treatment of acute exacerbations of interstitial lung disease.
Azadeh N; Moua T; Baqir M; Ryu JH
Expert Rev Respir Med; 2018 Apr; 12(4):309-313. PubMed ID: 29486130
[TBL] [Abstract][Full Text] [Related]
15. Aging and interstitial lung diseases: unraveling an old forgotten player in the pathogenesis of lung fibrosis.
Selman M; Rojas M; Mora AL; Pardo A
Semin Respir Crit Care Med; 2010 Oct; 31(5):607-17. PubMed ID: 20941661
[TBL] [Abstract][Full Text] [Related]
16. Cellular Senescence in Lung Fibrosis.
Hernandez-Gonzalez F; Faner R; Rojas M; Agustí A; Serrano M; Sellarés J
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34209809
[TBL] [Abstract][Full Text] [Related]
17. Clubbing in patients with fibrotic interstitial lung diseases.
van Manen MJG; Vermeer LC; Moor CC; Vrijenhoeff R; Grutters JC; Veltkamp M; Wijsenbeek MS
Respir Med; 2017 Nov; 132():226-231. PubMed ID: 29229102
[TBL] [Abstract][Full Text] [Related]
18. Nintedanib: a novel therapeutic approach for idiopathic pulmonary fibrosis.
Dimitroulis IA
Respir Care; 2014 Sep; 59(9):1450-5. PubMed ID: 24782550
[TBL] [Abstract][Full Text] [Related]
19. CCL18 in serum, BAL fluid and alveolar macrophage culture supernatant in interstitial lung diseases.
Cai M; Bonella F; He X; Sixt SU; Sarria R; Guzman J; Costabel U
Respir Med; 2013 Sep; 107(9):1444-52. PubMed ID: 23831213
[TBL] [Abstract][Full Text] [Related]
20. Expression analysis of angiogenic growth factors and biological axis CXCL12/CXCR4 axis in idiopathic pulmonary fibrosis.
Antoniou KM; Soufla G; Lymbouridou R; Economidou F; Lasithiotaki I; Manousakis M; Drositis I; Spandidos DA; Siafakas NM
Connect Tissue Res; 2010; 51(1):71-80. PubMed ID: 20067420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
